000			03733nam a22004215i 4500
001			85521
003			ES-MaUEC
005			20240611040143.0
007			cr nn 008mamaa
008			160330s2016 gw | s |||| 0|eng d
020			_a9783319289144
040			_aES-MaUEC
050		4	_aRM301.25 _b.N48 2016 EB
082	0	4	_a615
245	1	0	_aNew Approaches to Drug Discovery _cedited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch
250			_a1st ed.
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (VIII, 341 páginas) _b100 ilustraciones, 63 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aHandbook of Experimental Pharmacology _x0171-2004 _v232
505	0		_aPreface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
520			_aThis volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
650		7	_aFarmacología _xInvestigación _2embne _9183058
700	1		_aFuhrmann, Ulrike _eeditor literario _0Local _1http://viaf.org/viaf/306213435 _998546
700	1		_aJaroch, Stefan _eeditor literario _0Local _0http://id.loc.gov/authorities/names/n2006183654 _1http://viaf.org/viaf/40061910 _998547
700	1		_aNielsch, Ulrich. _eeditor literario _998545 _0Local _0http://id.loc.gov/authorities/names/nb2016010050 _1http://viaf.org/viaf/12146285351215370977
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-28914-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319289144
907			_a.b12947994 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11613907 _z30-06-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
988			_aEbook_one2one
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0
999			_c85521 _d85521 _x1